Sumitomo Pharma Oncology Receives Orphan Drug Designation for TP-3654, an Investigational Oral Inhibitor of PIM Kinases for the Treatment of Myelofibrosis

/PRNewswire/ -- Sumitomo Pharma Oncology, Inc., a clinical-stage company focused on novel cancer therapeutics, today announced the U.S. Food and Drug...

Related Keywords

United States ,China ,Japan ,Cambridge ,Cambridgeshire ,United Kingdom ,Sumitomo Pharma ,Jatinj Shah ,Patricias Andrews ,Prnewswire Sumitomo Pharma Oncology Inc ,Sumitomo Pharma Co Ltd ,Sumitomo Pharma Oncology Inc ,Pharma Oncology ,Orphan Drug Designation ,Global Head ,Sumitomo Pharma Oncology ,Drug Designation ,Chief Medical Officer ,Private Securities Litigation Reform Act ,Cleveland Clinic ,Nc ,